Big pharma companies strengthen their position in digital health with recent deals – Pharmaceutical Technology

In the last month, there have been several digital health merger and acquisition (M&A) and equity deals by big pharma companies.
By GlobalData Thematic Research
Digital health technologies can be used across the pharmaceutical value chain. For example, technologies such as apps and wearables are an integral part of decentralised clinical trials and are used for vital sign monitoring, collecting electronic clinical outcome assessments, facilitating virtual visits with investigators, and monitoring investigational drug adherence. They can also be used to generate and collect digital biomarkers, which are measures collected by sensors embedded in connected devices.
For example, microphones can be used to detect voice biomarkers, fine motor skills can be tested by swiping and typing on touch screens, and electrocardiogram sensors in smartwatches can measure heart rate variabilities to detect conditions such as atrial fibrillation. In post-marketing settings, real-world evidence generated from digital devices can provide a better understanding of product tolerability and toxicity profiles, provide better insights into drivers of adherence, enable remote monitoring of product safety, and integrate the patient experience into research. In sales and marketing, they can be used in ‘beyond the pill’ services and provide medication adherence, remote monitoring, chronic disease management and decision support tools for patients and healthcare professionals (HCPs).
To implement these technologies, pharma companies typically forge partnerships and collaborations with different digital health companies, be they virtual trial vendors, wearable technology providers or mobile app and digital therapeutic developers. In the last month, however, there have been several digital health merger and acquisition (M&A) and equity deals by big pharma companies.
Last month, it was announced that AstraZeneca intended to acquire a stake worth up to £25m ($33m) in Huma, a UK-based company whose platform supports digital ‘hospitals at home’ and supports decentralised clinical trials. The platform combines predictive algorithms, digital biomarkers and real-world data to support ‘proactive, predictive care and research’. At the same time, Huma will acquire AstraZeneca’s AMAZE, a disease management platform for asthma and heart failure patients. The two companies also plan to partner to launch software as a medical device companion apps for mobile devices, as well as expedite the adoption of decentralised clinical trials.
Related
This month, it was announced that Pfizer Australia plans to acquire ResApp Health for around A$100m ($75m). ResApp Health has developed smartphone apps for the diagnosis and management of respiratory diseases, such as pneumonia, asthma, bronchiolitis and chronic obstructive pulmonary disease (COPD). The technology uses artificial intelligence to diagnose and measure the severity of conditions using the sound of a patient’s cough. Two apps have been approved for marketing in Australia and Europe: ResAppDx can differentiate respiratory diseases and can be used in telehealth, emergency department and primary care settings, while SleepCheck allows people to self-assess their risk of sleep apnoea.
ResApp recently announced that the first UK pilot of ResAppDx as an outpatient clinic tool in the Dartford and Gravesham NHS Trust will start this year. The company has also developed a smartphone-based screening test for Covid-19 during the pandemic. At the same time, Pfizer and ResApp have agreed to a research and development (R&D) partnership into Covid-19 diagnostics, initially for six months with the option to extend.
Because of Covid-19 lockdown and social distancing measures, there has been a surge in demand for alternatives to in-person care, with many areas of digital health thriving such as virtual trials, telemedicine and remote patient monitoring. As a result, many technologies that allow the remote monitoring of patients have found a permanent place in the delivery of care, as the benefits to multiple stakeholders have been shown to be wide-reaching. The pharma industry needs to capitalise on this new era of healthcare and must integrate these technologies across its value chain to support its customers. GlobalData expects further deal-making activity besides traditional partnerships as pharma companies look to strengthen their digital health offerings.
Valves and Accessories for the Pharmaceutical Industry
Development Services and Programmes for Healthcare Companies
Analytical Services for Biological Assays

source

Share:

More Posts

Market Research

Pulse Surveys

Turn feedback into action

Our survey platform makes it easy to measure and understand feedback so you can drive growth and innovation

Pulse Handshak

Pulse Handshak

Collaborative online survey tool for the market research industry. Remote assisted surveying just like face-to-face interviews. Here interviewers can talk to the respondent over the web-console without the need for any other communication channel and share the same Q're with responses and click actions.

Pulse FE

Pulse FE

Pulse Field Expert or Pulse FE is the main platform for both offline and online survey at softofficepro.com. It is robust and used by hundreds of clients over tens of years with millions of responses. Do it once Q're and deploy on both offline devices (android) and online forms makes it a great cost effective platform for any kind of responses

Pulse Ultimate

Pulse Ultimate

Pulse Ultimate is targeted for tracking studies and retail audits. An offline survey system offering extreme field control including processes like data quality check, back-check, rework, comparison with previous wave data etc. helps to get the best results on a day-to-day basis

Pulse LS

Pulse LS

Use a managed Limesurvey and our expertise for creating complex forms and token based user management. Use optional mailing system to send survey invitation to each participant and track progress of the response status. Industry standard SPSS / R output supported